LexaGene Sells a MiQLab System to Denver Animal Emergency
June 07 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce Denver Animal Emergency has provided LexaGene a
purchase order for a MiQLab System™.
Dr. Andrew Pierce, Owner and Medical Director of Denver Animal
Emergency in North Carolina, states, “We have been using LexaGene’s
MiQLab for several months as part of their Early Access Program.
We’ve compared the accuracy of the MiQLab to results generated by
culture and there was such high concordance, we have found that we
are running MiQLab more often than we are sending samples out for
culture.”
Dr. Andrew Pierce went on to say, “The MiQLab identifies not
just the most common pathogens, but also many common antimicrobial
resistance factors. Knowing this information soon after seeing the
animal has boosted our confidence that our prescribed therapies
will effectively treat the infection, even if it is found to be
resistant to some antibiotics. Our veterinarians have enjoyed using
it so much, and our clients are benefiting with better care, so it
was an easy decision to purchase the system.”
A testimonial from Dr. Pierce is available HERE.
Dr. Jack Regan, LexaGene’s Founder and CEO comments, “I’m
pleased that Dr. Pierce and his team at Denver Animal Emergency has
decided to purchase the MiQLab System. Dr. Pierce is sending a
strong message to his patients that the benefits of point-of-care
diagnostics, time to result and high concordance will lead to
improved animal care and better medical outcomes for our companion
animals. This is exactly why LexaGene is in veterinary health and
why we aim to change the way veterinary diagnostics are done. No
longer is it necessary to wait days for culture when you can have
such a powerful point of care diagnostic tool like the MiQLab.”
Dr. Jack Regan went on to say, “I’m excited to report that our
newly hired veterinary, sales representatives are pursuing many
promising leads throughout their territories. Their enthusiasm
continues to grow as veterinarians are expressing their desire for
in-hospital diagnostics. We look forward to announcing more
veterinary sales soon.”
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
For inquiries: 800.215.1824 | ir@lexagene.com or
info@lexagene.com
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
About Denver Emergency HospitalDenver Animal
Emergency, located in Denver, North Carolina is Lincoln County’s
only 24/7 Emergency and Critical Care animal hospital. Denver
Animal Emergency offers emergency care, overnight hospitalization,
advanced diagnostics, emergency surgery and much more. The hospital
employs close to 30 employees and operates 24 hours, 7 days a week,
365 days a year, including holidays. The hospital was established
by Dr. Andrew Pierce in 2016 to better serve the community’s
emergency animal needs and has seen tremendous growth throughout
its first 5 years.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024